Venus Concept Inc. Announces Issuance of $2.0M of Convertible Notes
- None.
- None.
Insights
The issuance of secured convertible notes by Venus Concept represents a strategic financial maneuver aimed at enhancing the company's liquidity. The $2.0 million raised through this debt instrument is a relatively modest sum, which suggests that the company is looking to shore up its finances without significantly diluting shareholder equity. The decision to opt for convertible notes rather than straight debt or equity financing indicates a balancing act between the desire for capital and the need to manage potential dilution.
The addition of a mandatory redemption provision tied to specific events, such as receiving employee retention credits, introduces a layer of complexity to the terms of the notes. This clause could potentially accelerate repayment obligations, thereby impacting the company's cash flow management. The use of Adjusted SOFR as a benchmark for the interest rate reflects a contemporary approach to interest rate setting, post-LIBOR era and the 8.5% premium over this rate suggests a higher risk profile associated with the investment.
For investors, the conversion price of $1.251 per share will be a critical figure, as it will determine the extent of future dilution if the notes are converted. The fact that the company has committed to filing a registration statement for the resale of the common stock upon conversion demonstrates a proactive approach to regulatory compliance and liquidity provision for note holders.
The medical aesthetic technology sector is characterized by high capital expenditure and a competitive landscape. Venus Concept's mention of restructuring activities aimed at improving profitability in international markets indicates an ongoing strategic shift. The softer-than-expected revenue results for Q4 2023 could be symptomatic of broader market challenges, such as the financing environment for customers. It is essential to monitor how this environment evolves, as it can significantly affect sales of high-value medical equipment.
Investors and stakeholders should consider the company's performance against industry benchmarks for cash flow management and operational efficiency. The stated goal of reducing cash used in operations by 50% year-over-year is an ambitious target that, if achieved, could signal a positive turnaround and improved financial health. However, the company's ability to meet its strategic objectives amidst market challenges will be a key determinant of its future performance.
The legal framework surrounding the issuance of convertible notes is intricate, requiring strict adherence to securities laws. Venus Concept's adherence to the Securities Act of 1933 by not offering the securities in a public offering and the commitment to file a registration statement with the SEC for the resale of the common stock is a prudent move to ensure regulatory compliance. This approach mitigates legal risk and provides transparency for investors regarding the potential future conversion of notes into equity.
Moreover, the stipulation that the securities may not be offered or sold in the United States absent registration or pursuant to an exemption from registration requirements is a standard safeguard to protect both the company and investors. It is crucial for investors to understand the implications of these legal conditions, as they affect the liquidity and marketability of the securities involved.
Sale of convertible notes provides additional financial flexibility and support for the Company’s path to cash flow breakeven
TORONTO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Venus Concept, Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has issued new secured convertible notes to EW Healthcare Partners, L.P. and one of its affiliates (“EW Healthcare”) in an aggregate principal amount of
“I want to thank EW Healthcare for their valuable partnership and support of the Company over many years,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “While our fourth quarter 2023 revenue results were softer-than-expected due to the impact of restructuring activities related to improving profitability in our international markets and the difficult financing environment for customers in all markets including the US, we are pleased to deliver on our primary objective for 2023 - to reduce our cash used in operations by approximately
Additional information regarding the convertible notes will be set forth in a Current Report on Form 8-K, which the Company expects to file with the Securities and Exchange Commission (“SEC”) today.
The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “1933 Act”), or applicable state securities laws. The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. The Company has agreed to file a registration statement covering the resale of the Common Stock issuable upon conversion of the notes.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities in the described offering, nor shall there be any offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking” statements within the meaning of Section 27A of the 1933 Act and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements about the Company’s financial condition, and other statements containing the words “expect,” “intend,” “may,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond the Company’s control. Factors that could materially affect the Company’s business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part I Item 1A—“Risk Factors” in the Company’s most recent Annual Report on Form 10-K, Part II Item 1A—“Risk Factors” in the Company’s most recent Form 10-Q and in other documents the Company may file with the SEC. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to the Company as of the date hereof. Unless required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.
About Venus Concept
Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 14 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.
FAQ
What is the principal amount of the convertible notes issued by Venus Concept, Inc.?
What is the maturity date of the convertible notes?
What is the annual interest rate of the convertible notes?
Who are the convertible notes convertible into?
What is the initial conversion price of the convertible notes?
